Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002165
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Viracept Expanded Access Program
Sponsor:
Agouron Pharmaceuticals
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Viracept Expanded Access Program
Status:
COMPLETED
Status Verified Date:
1996-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To make nelfinavir mesylate Viracept available for treatment of HIV positive patients who are unable to take the three commercially available protease inhibitors because of failure intolerance or contraindication and who have a CD4 cell count of 50 To obtain additional information on the safety profile of nelfinavir mesylate Viracept
PER AMENDMENT 1897 People now qualify for the Viracept Program if they are unable to take indinavir andor ritonavir due to intolerance contraindication or prior failure
PER AMENDMENT 1897 People now qualify for the Viracept Program if they are unable to take indinavir andor ritonavir due to intolerance contraindication or prior failure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AG1343 - 515 | None | None | None |
| Study 515 | None | None | None |